Tan Eng S, Rienstra Michiel, Wiesfeld Ans C P, Schoonderwoerd Bas A, Hobbel Hugo H F, Van Gelder Isabelle C
Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
Europace. 2008 Apr;10(4):412-8. doi: 10.1093/europace/eun020. Epub 2008 Feb 12.
To investigate long-term outcome and to determine predictors of development of heart failure (HF) in patients with atrioventricular (AV) node ablation and permanent right ventricular pacing because of symptomatic refractory atrial fibrillation (AF).
Atrioventricular node ablation and subsequent permanent pacing is a well-established therapy for patients with AF. Long-term right ventricular pacing may induce HF.
In 121 (45 with previous HF) patients with drug refractory AF, AV node ablation and implantation of a pacemaker was performed. At baseline and after a mean follow-up of 4.3 +/- 3.3 years, New York Heart Association (NYHA) functional class for HF and left ventricular (LV) and atrial diameters were assessed. During and at the end of follow-up, hospitalizations for HF, mortality, and quality of life were assessed using the SF-36 and an AVN-specific questionnaire. No significant changes in NYHA functional class (87 vs. 77% in NYHA I/II at baseline vs. end of follow-up) and LV end diastolic diameter (51 +/- 7 vs. 52 +/- 8 mm) were observed. Left ventricular end systolic diameter decreased (from 37 +/- 9 to 34 +/- 7 mm, P = 0.03) and fractional shortening improved (from 28 +/- 10 to 34 +/- 9, P = 0.02) in all patients and in patients with previous HF, but not in patients without previous HF. Hospitalizations for HF occurred in 24 patients (20%), predominantly those with previous HF. All-cause mortality occurred in 31 (26%) patients. At the end of follow-up, quality of life was comparable with the control group.
Long-term outcome of AV node ablation and permanent pacing is good. Atrioventricular node ablation remains a treatment option for AF.
研究房室结消融及永久性右心室起搏治疗有症状难治性心房颤动(房颤)患者的长期预后,并确定心力衰竭(心衰)发生的预测因素。
房室结消融及随后的永久性起搏是房颤患者的一种成熟治疗方法。长期右心室起搏可能诱发心衰。
对121例(45例既往有心衰)药物难治性房颤患者进行了房室结消融并植入起搏器。在基线时以及平均随访4.3±3.3年后,评估纽约心脏协会(NYHA)的心衰功能分级以及左心室(LV)和心房直径。在随访期间及结束时,使用SF-36和一份房室结特异性问卷评估心衰住院情况、死亡率及生活质量。未观察到NYHA功能分级(基线时NYHA I/II级为87%,随访结束时为77%)和左心室舒张末期直径(51±7 vs. 52±8 mm)有显著变化。所有患者以及既往有心衰的患者左心室收缩末期直径减小(从37±9减小至34±7 mm,P = 0.03),射血分数改善(从28±10提高至34±9,P = 0.02),但既往无心衰的患者未出现上述变化。24例患者(20%)因心衰住院,主要是既往有心衰的患者。31例(26%)患者全因死亡。随访结束时,生活质量与对照组相当。
房室结消融及永久性起搏的长期预后良好。房室结消融仍是房颤的一种治疗选择。